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Abstract: Background: Von Willebrand factor (vWF) has been proposed
as a major contributor to the development of coagulopathy in pulmo-
nary xenotransplantation. Pretreatment of donor swine with 1-deamino-
8-d-arginine vasopressin (DDAVP), an analog of vasopressin, can
reduce the content of vWF in pulmonary xenografts. Here, we investi-
gate the effects of DDAVP pre-treatment in an ex-vivo perfusion model
of pulmonary xenotransplantation.
Methods: We set up and performed the ex-vivo perfusion using porcine
pulmonary accessory lobes and fresh human whole blood (n = 12).
Half of the donor swine were given 3 lg/kg DDAVP intravenously for
3 days before ex-vivo perfusion (DDAVP group) and half of them were
left untreated (control group). The porcine lung was perfused with fresh
blood for 1 h and changes in the following parameters were monitored:
pulmonary arterial pressure, pulmonary vascular resistance, blood cell
counts, fibrinogen, antithrombin, platelet factor 4, D-dimer, C3a, C4d,
and xenoreactive IgM. The release of Gala1-3Gal xenoantigen (aGal)
from porcine lung which had been perfused and retained for 30 min with
human blood was assessed by enzyme-linked immunosorbent assay
using aGal-binding lectin.
Results: Both DDAVP and control groups showed typical findings of
immediate pulmonary dysfunction: an increase of pulmonary vascular
resistance and sequestration of leukocytes and platelets after ex-vivo
perfusion. However, in the DDAVP group, the increase of platelet
factor 4, C3a, and C4d after perfusion was attenuated compared to
that in the control group. The release of aGal after blood retention
was significantly lower in the DDAVP group than that of the control
group.
Conclusion: Pre-infusion of DDAVP to the donor swine was beneficial
in attenuating platelet activation as well as complement/coagulation
activation. These effects of DDAVP are likely to relate to the
reduction of porcine vWF content in the xenograft. Therefore, the
modulation of vWF secretion in donor lungs could be an additional
therapeutic way to reduce systemic coagulopathy in pulmonary xeno-
transplantation.
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Xenotransplantation using porcine organs is a
promising alternative solution to overcome the
shortage of human donor organs. Hyperacute
rejection, the first hurdle for xenotransplantation,
could be overcome using porcine organs genetically
engineered to overexpress human complement
regulatory proteins or to lack the major xenoan-
tigen, Gala1-3Gal (aGal) [1]. These strategies
enabled us to prolong the survival of porcine
xenografts transplanted to non-human primates up
to several months or weeks in cardiac and renal
transplantation [2–5]. However, in the case of
pulmonary xenotransplantation, xenografts under-
go a rapid failure immediately after exposure to
human or primate blood [6–8], characterized by
elevated pulmonary vascular resistance (PVR) and
pulmonary edema associated with vascular throm-
bosis [7], despite these strategies. Intravascular
thrombosis accompanying systemic coagulopathy
is a main pathologic feature of pulmonary xeno-
grafts while tissue necrosis and hemorrhages are
the main attributes of cardiac or renal xenograft
hyperacute rejection [9].
Von Willebrand factor (vWF) has been pro-
posed as a major contributor to the development of
coagulopathy in pulmonary xenotransplantation
[9,10]. Porcine vWF released from activated endo-
thelial cells of xenografts not only promotes
platelet adhesion and activation on the surface of
endothelial cells, but also provides binding sites for
xenoreactive antibodies because of its abundant
aGal moiety. The immune complexes of xenoreac-
tive antibodies and vWF on swine endothelial cells
are shed into the circulation and lead to systemic
coagulation abnormality [11]. We have previously
demonstrated that pre-treatment of donor
swine with 1-deamino-8-d-arginine vasopressin
(DDAVP), an analog of vasopressin, can reduce
the content of vWF in pulmonary xenografts and
ameliorate platelet sequestration in the swine-to-
canine pulmonary xenograft model [12]. Accord-
ingly, we asked if DDAVP pre-treatment would be
beneficial in swine-to-human xenotransplantation.
Consequently, we investigated the effect of
DDAVP pre-treatment of donor swine in an
ex-vivo perfusion pulmonary xenotransplantation
model.
Materials and methods
Treatment of donor with DDAVP
All of the animals in the study were treated
humanely in compliance with the ‘‘Guide for the
Care and Use of Laboratory Animals’’ published
by the National Institutes of Health (NIH Publi-
cation No. 86–23, revised 1985). DDAVP treat-
ment was performed as previously described [12].
Briefly, six adult donor swine (22 to 35 kg) were
anesthetized with intramuscular administrations of
ketamine hydrochloride (20 mg/kg) and were intu-
bated and ventilated with 100% oxygen at a rate of
10 times/min with a tidal volume of 12 ml/kg. A 9
Fr. Hickman catheter (Bard Access Systems, Salt
Lake City, UT, USA) was inserted into the
external jugular vein through the neck incision
and the tip was placed in the back. DDAVP (3 lg/
kg; Ferring Pharmaceuticals Inc., Suffern, NY,
USA) was injected every 12 h intravenously
through the Hickman catheter for 3 days until
experiment of ex-vivo perfusion. Blood was sam-
pled at the time of insertion of the Hickman
catheter and at the time of organ harvest.
Ex-vivo perfusion set up
The human blood for perfusion was donated from
healthy volunteers with B+ blood type. The blood
donation for research purposes was approved by
the Institutional Review Board (IRB H-0412-138-
013). Four hundred microliters of blood was drawn
in a blood bag containing the anticoagulant citrate-
phosphate-dextrose-adenine at 2 to 3 h before the
ex-vivo perfusion. The blood was diluted with the
same volume of Hartmann’s solution and was
added with 2 units/ml of heparin sodium and
1.3 mg/ml of CaCl2. The perfusate was primed in
the ex-vivo perfusion circuit.
Lung harvest
Six swine for each DDAVP-infused and control
group were used for the experiment. Each animal
was anesthetized by intramuscular injection of
ketamine hydrochloride (20 mg/kg), xylazine
(1 mg/kg), and atropine (0.2 mg). After endotra-
cheal intubation, general anesthesia was main-
tained with sevofluene gas inhalation and
intermittent vecuronium administration. The ani-
mal was ventilated with a tidal volume of 15 ml/kg
and respiration rates of 15 times/min. A right
thoracotomy was placed and the pleural cavity was
entered though the top of 7th rib. The accessory
lobe was identified by opening of the pleural
investment and the pulmonary artery, vein, and
bronchus were dissected. The fissure was carefully
divided, avoiding parenchymal damage. The ani-
mal was heparinized (300 units/kg) and the acces-
sory lobe was harvested. We divided the
pulmonary artery before division of the pulmonary
vein to avoid any chance of congestion of the graft.
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After that, the bronchus was divided. The resected
accessory lobe was placed in cold preservation
solution and the pulmonary artery was cannulated
with 8 Fr. aortic cannula, through which prosta-
glandin (PG) E1 (Eglandin; 4 lg/kg, Welfide,
Hwaseong, Korea) was infused. The accessory lobe
was then perfused with 4 C modified Euro-Collins
preservation solution (100 ml/kg). During the per-
fusion, the accessory lung was ventilated through
the bronchial cannula with room air. After perfu-
sion, the pulmonary vein was cannulated for ex-vivo
perfusion. A portion of the remaining right upper
lobe was sampled for tissue control. The left lung
was harvested for the perfusate retaining model.
Ex-vivo perfusion model
The accessory lobe was connected to the ex-vivo
circuit. The perfusion was slowly started and the
flow rate was increased gradually to reach 20 ml/
min at the pulmonary venous drain site. The graft
was ventilated with room-air at 20 ml of tidal
volume and 20 times/min of respiratory frequency
using a Harvard rabbit ventilator (Hugo Sachs
Elektronik, March Hugstetten, Germany). The
temperature was maintained at 37 C with a heat-
exchanger and water bath. The perfusion pressure
was monitored and blood was sampled at both
pulmonary arterial and venous sides at 10, 30, and
60 min after perfusion. After 60 min of perfusion,
the graft tissue was obtained.
Perfusate retaining model
The left pulmonary artery was cannulated with a
24 Fr. aortic cannula and was perfused with PGE1
and cold Euro-Collins solution. The 200 ml of
perfusate (1 : 1 mixture of human blood and
Hartmann’s solution) was infused through the
cannula at 40 cm height and the pulmonary vein
was clamped. After 30 min of retention, the
pulmonary venous clamp was released and the
retained blood was drawn and sampled.
Measurement of blood cell counts and coagulation/complement
activation markers
We monitored changes in the following parameters
up to 60 min after reperfusion: blood cell counts,
and plasma levels of fibrinogen, antithrombin III,
D-dimer, platelet factor 4 (PF4), C3a, and C4d.
Blood cell count was measured by ABCvet CBC
analyzerTM (ABX hematology, Montpellier Cedex,
France) and coagulation parameters including
fibrinogen, antithrombin III, and D-dimer by
STA Compact analyzer TM (Diagnostica Stago,
Asnières, France). PF4 was assayed by enzyme-
linked immunosorbent assay (ELISA) using the
Asserachrom PF4 kit (Diagnostica Stago). The
complement activation fragments C3a and C4d
were also measured by ELISA kits (Quidel, San
Diego, CA, USA). Each parameter was expressed
as a percentage of baseline value prior to reperfu-
sion.
Assessment of circulating xenoreactive IgM and IgG
Flow cytometric analysis was performed to detect
IgM and IgG xenoreactive antibodies. Porcine
aortic endothelial cells (PAEC) were purchased
from Cell Applications (San Diego, CA, USA).
Briefly, 5 · 105 PAEC were incubated with 50 ll of
plasma in each tube for 30 min at 37 C. In
parallel, the cells were incubated with phosphate-
buffered saline (PBS) as a negative control, and
with a serial dilution of the selected human plasma
as a calibrator, which was confirmed to have high
titer of IgM antibodies against PAEC. The cells
were washed with PBS and then incubated with
100 ll of 1 : 200 diluted rabbit anti-human IgM
(Dako Corp., Carpinteria, CA, USA) or fluores-
cein isothiocyanate (FITC)-labeled rabbit anti-
human IgG (Dako Corp.) for 30 min at 37 C .
The cells incubated with unlabeled anti-human
IgM were further stained with 1 : 200 diluted
FITC-labeled anti-rabbit IgG (ICN Pharmaceuti-
cals, Inc., Aurora, OH, USA) for 30 min at 37 C
in the dark. After washing, the cells were fixed with
500 ll 1% paraformaldehyde and then analyzed on
a FACScan flow cytometer (BD Biosciences, San
Jose, CA, USA). The geometric mean fluorescent
intensity of each sample was compared to those of
the negative control and the calibrator. The
amount of binding antibody was expressed as an
artificial unit (AU)/ml compared to the mean
fluorescent intensity of undiluted calibrator desig-
nated as 100 AU/ml.
Measurement of aGal level in perfusate
The level of aGal in perfusate was determined by
ELISA using a Griffonia simplicifolia lectin (GSL)
I-isolectin B4 (Vector laboratories, Burlingame,
ON, Canada) coated plate and biotinylated GSL
I-isolectin B4 (Vector laboratories). Briefly, the
microwell plate was coated with 10 lg/ml GSL I-
isolectin B4 in carbonate buffer (15 mm Na2CO3
and 35 mm NaHCO3, pH 9.6) overnight at 4 C.
The wells were blocked with Tris-buffered saline
(TBS), pH 8.0 containing 1% bovine serum albu-
min for 1 h. Each well was reacted with 100 ll of
1/10 diluted serum in TBS for 30 min at 37 C. The
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pooled normal swine serum serially diluted in
normal human serum was tested in parallel and
used as a control. After being washed with TBS
containing 0.05% Tween 20, the wells were reacted
with 100 ll of 1 lg/ml biotinylated GSL I-isolectin
B4 for 30 min at 37 C and then 100 ll of 1 : 2000
diluted horseradish peroxidase-conjugated strepta-
vidin (Dako Corp.) for 30 min at 37 C. After
washing, the color reaction was developed and the
absorbance at 450 nm was measured.
Statistical analysis
Data are expressed as mean ± standard error of
the mean. Comparisons between groups were
analyzed using a mixed model which is a type of
repeated measures analysis but applicable to anal-




The pulmonary arterial pressure increased in both
control and DDAVP groups after perfusion with
human blood (P = 0.001). Initially, the mean
pulmonary arterial pressure was 37.0 ±
18.0 mmHg and 46.3 ± 14.6 mmHg in the control
and DDAVP groups, respectively. After 60 min
perfusion, it increased to 57.5 ± 7.3 mmHg and
68.0 ± 1.0 mmHg in control and DDAVP groups,
respectively. Compared to the control group, the
DDAVP group showed higher pulmonary arterial
pressure (P = 0.022). In the control group, pul-
monary vascular resistance increased from
1.8 ± 0.6 mmHg/ml/min to 3.0 ± 0.5 mmHg/
ml/min, and in DDAVP group, from
2.2 ± 1.4 mmHg/ml/min to 3.0 ± 0.1 mmHg/
ml/min. There was, however, no statistically sig-
nificant difference between the two groups
(P = 0.635).
DDAVP pre-treatment prevents subsequent hemoconcentration
after perfusion.
We monitored blood cell counts in the perfusate
prior to and during the perfusion. The initial blood
counts were not different between groups. Imme-
diately after the start of perfusion, platelet counts
in both groups rapidly decreased within 10 min
and remained low throughout the experiment
(Fig. 1). Leukocyte counts gradually decreased
with time and there was no difference between
groups. Hemoglobin levels in the whole blood
gradually increased during the experiment in both
groups but the increase in the control group was
higher than that of the DDAVP group
(P = 0.032), suggesting that hemoconcentration
developing during the perfusion was severer in the
control group than in the DDAVP group.
DDAVP pre-treatment attenuates systemic coagulation
abnormalities and platelet activation
We timely measured the fibrinogen, antithrombin
III, and D-dimer levels in perfusate to monitor the
coagulation system. Fibrinogen and antithrombin
III levels did not change significantly during the
perfusion and were not different between groups
(Fig. 2). The D-dimer level in the control group
occasionally increased during the perfusion and
Fig. 1. Changes in hematological parameters: leukocyte and
platelet counts and hemoglobin level during ex-vivo perfusion.
Half of donor swine were given 1-deamino-8-D-arginine
vasopressin (DDAVP, 3 lg/kg) intravenously every 12 h for
3 days before ex-vivo perfusion (n = 6 for each group). The
porcine lung was perfused with fresh human whole blood and
its hematological parameters were monitored for 60 min. Each
value at a given time point is expressed as the percentage of the
initial measurement. Increases in hemoglobin levels were higher




tended to be higher than that of the DDAVP group
(P = 0.138). In the DDAVP group, the level of
D-dimer remained in the normal range throughout
the duration of perfusion.
The level of PF4 was also measured to monitor
platelet activation. It increased steadily during
perfusion in both groups. However, the increase
was significantly less in the DDAVP group than
that of the control group (P < 0.001, Fig. 2),
demonstrating that the extent of platelet activation
was less in the DDAVP group compared to
controls.
DDAVP pre-treatment reduces complement activation in ex-vivo
perfusion model
To evaluate activation of the complement system,
C3a and C4d were monitored during perfusion. In
the control group, C3a and C4d levels increased
within 10 min after perfusion and were maintained
at high concentrations throughout the experiment
(Fig. 3). However, the DDAVP group showed only
a small increase in C3a and C4d levels during the
perfusion and their C3a and C4d levels tended to
be lower than those of the control group
(P = 0.057, 0.058), indicating that less systemic
complement activation occurred in the DDAVP
group.
aGal release from xenograft diminishes in DDAVP pre-treated
group
In the next step, we asked how DDAVP pre-
treatment can reduce complement activation. Por-
cine vWF is known to carry a lot of aGal moiety,
Fig. 2. Changes in coagulation parameters: fibrinogen, anti-
thrombin III, platelet factor 4 (PF4), and D-dimer during ex-
vivo perfusion. Porcine lungs of both DDAVP pretreated and
control groups were perfused with fresh human blood for
60 min and blood was sampled at the given time points. Four
coagulation parameters were assayed. In the DDAVP group,
D-dimer levels tended to be lower than those of the control
group and PF4 levels were significantly lower (*P = 0.138;
P < 0.001).
Fig. 3. Changes in complement activation products: C3a and
C4d during ex-vivo perfusion. Each DDAVP pretreated and
control porcine lung was perfused with fresh human blood for
60 min and C3a and C4d in the plasma were monitored. C3a
and C4d levels increased within 10 min after perfusion but the
increase of each during perfusion tended to be lower in
the DDAVP group than in the control group (*P = 0.057;
P = 0.058).
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which is a main xenoantigen. We hypothesized that
depletion of vWF by DDAVP pre-treatment would
reduce the amount of vWF released into the
circulation, which would lead to the subsequent
reduction of complement activation and systemic
coagulation. To determine the amount of released
aGal antigen, we tried to detect aGal by ELISA
using GSL I-isolectin B4 in the perfusate timely
drawn during the ex-vivo perfusion. However, we
failed to demonstrate the presence of aGal in the
perfusate of either group (data not shown). We
designed a perfusate retaining model with the
expectation of exaggerated responses of endothelial
cells. Each xenograft was perfused and retained for
30 min without circulation, and the perfusate was
obtained thereafter. aGal was easily detectable by
ELISA and its level was higher in the control group
than in the DDAVP group (P = 0.0317, Fig. 4),
demonstrating that DDAVP pre-treatment reduces
the release of aGal from xenograft into the
circulation.
The initial level of IgM anti-swine antibodies in the perfusate
was not different between groups
Complement activation in xenografts is known to
depend on the level of anti-swine antibody in
circulating blood. The less complement activation
in the DDAVP group might have been caused by
low anti-swine antibody levels of each blood
donor. To exclude this possibility, we measured
the level of anti-PAEC antibodies in the blood by
flow cytometry. The blood used in each experiment
showed a variable level of IgM antibodies against
PAEC, but on average, the initial level of IgM anti-
PAEC antibodies in the perfusate was not different
between groups (Fig. 5). The level of IgM anti-
PAEC antibodies rapidly decreased after perfusion
in both groups suggesting xenoreactive IgM anti-
bodies are captured and sequestered in the xeno-
graft. We tried to measure IgG antibodies against
PAEC but failed to detect any significant binding
of IgG antibodies to cells (data not shown).
Discussion
In this study, we demonstrated that DDAVP pre-
treatment of donor swine reduces adverse res-
ponses related to platelet activation and systemic
coagulation/complement activation in an ex-vivo
perfusion model of pulmonary xenotransplanta-
tion. When porcine lung was perfused with fresh
human blood, blood platelet counts rapidly
dropped and the levels of D-dimer, PF4, and
complement activation fragments increased, sug-
gesting that platelets were activated and seques-
tered into the xenograft, subsequently resulting in
intravascular coagulation and complement activa-
tion. However, in DDAVP pre-treated group, the
degree of increase for D-dimer, PF4, C3a, and C4d
after ex-vivo perfusion was attenuated and their
post-perfusion levels were significantly lower than
those of the control group.
The DDAVP is known to induce vWF secretion
from endothelial cells [13]. Porcine vWF is consid-
ered a culprit for intravascular thrombosis and
Fig. 4. aGal release from DDAVP treated and control porcine
lungs. Each lung was perfused with fresh human blood and
retained for 30 min (n = 6 for each group). The blood was
obtained before and after 30 min retention. Serum aGal was
captured on GSL I-isolectin B4 coated wells and detected by
biotinylated GSL I-isolectin B4 and subsequent color devel-
opment. aGal level was higher in the control group than in the
DDAVP group (*P = 0.0317).
Fig. 5. Change of xenoreactive IgM antibody titer during
ex-vivo perfusion. Each lung of DDAVP pretreated or control
swine was perfused with fresh human blood for 60 min and
blood was obtained at given time points. Porcine aortic
endothelial cells were incubated with each serum, sequentially
reacted with rabbit anti-human IgM and FITC-labeled anti-
rabbit IgG, and analyzed with a flow cytometer. The titer of
xenoreactive IgM antibody was determined by the mean fluo-
rescent intensity of each serum and expressed as an artificial
unit (AU)/ml compared to the mean fluorescent intensity of
undiluted calibrator designated as 100 AU/ml. There was no
significant difference in the initial titer and overall change of




systemic coagulation in pulmonary xenotransplan-
tation [9,11]. Following exposure to human blood,
porcine endothelial cells are activated possibly by
multiple stimuli, such as ischemic or mechanical
injury, and binding of xenoreactive antibodies with
or without subsequent complement activation,
leading to exposure of pro-coagulant and pro-
inflammatory surfaces and expression or secretion
of P-selectin, vWF, and platelet-activating factor
[14–16]. Porcine vWF binds to human platelets and
induces their activation and aggregation [17]. A
study of swine-to-baboon pulmonary xenotrans-
plantation using vWF-deficient donors has shown
that vWF-deficient xenografts exhibit interstitial
hemorrhage and edema instead of intravascular
thrombosis, one of the typical features of pulmo-
nary xenotransplantation rejection [9]. This sug-
gests that porcine vWF is the key molecule for the
development of intravascular thrombosis in pul-
monary xenografts. In previous study, we demon-
strated that pre-treatment of donor swine with
DDAVP reduces the content of vWF in swine lung
without up-regulation of vWF synthesis [12]. The
DDAVP treatment of donor swine reduced the
content of vWF Ag in porcine lung tissue by 52%
(DDAVP-treated group vs. control group,
7.7 ± 2.4 AU/mg vs. 16.0 ± 5.6 AU/mg). We
speculate that about 50% of vWF would be left
in porcine lung tissue after treatment even though
the exact distribution and functional impact is
unknown. We have previously shown that
DDAVP pre-treatment of donor swine attenuates
the decrease of blood platelet counts in swine-to-
canine pulmonary xenotransplantation [12]. In this
study, DDAVP pre-treatment could not prevent
the decrease of platelet counts in human blood
after ex-vivo perfusion. However, it certainly
reduced the increase of PF4 which is a platelet
activation marker. D-dimer, a marker of systemic
intravascular coagulation, remained in the normal
range in the perfusion of DDAVP pre-treated
porcine lungs, while it frequently increased in that
of control lungs. These beneficial effects of
DDAVP which were shown not only in the contact
with canine blood but also in that with human
blood can be attributable to the possible reduc-
tion of vWF content in xenografts by DDAVP
treatment.
Porcine vWF is also known to contain aGal, a
major antigen for xenoreactive antibodies [18].
When activated, porcine pulmonary endothelial
cells shed vWF along with other membrane pro-
teins [11], which forms circulating immune com-
plexes with xenoreactive antibodies, leading to type
III immune complex disease and disseminated
intravascular coagulation [11]. To further explore
the DDAVP effect on the formation of immune
complexes, we first tried to demonstrate the pres-
ence of circulating porcine-vWF/IgM immune
complex in blood by ELISA but failed to get a
positive signal. Next, we tried to measure the
amount of aGal released into circulating blood by
ELISA using GSL I-isolectin B4. Disappointingly,
aGal was not detected in blood samples from the
ex-vivo perfusion model. However, the signal in the
positive control well tested in parallel was clearly
positive. We assumed that the concentration of
released aGal was too low to be detected by our
ELISA system. Consequently, we designed a per-
fusate retaining model to concentrate aGal in the
blood. Soluble aGal was not detected in blood
samples obtained before retention but it was
obviously detectable by ELISA in samples obt-
ained after retention. Its concentration was signif-
icantly higher in the control group than in the
DDAVP group. This finding demonstrates that
DDAVP pre-treatment reduces the release of aGal
from xenografts into the circulation. We speculate
that shed porcine vWF would be an important
source of circulating aGal in xenotransplantation
and partial depletion of vWF by DDAVP provides
a benefit in the reduction of aGal release and its
immune complex formation, and in the prevention
of subsequent complement and coagulation acti-
vation. Lower level of C3a and C4d in the
perfusate of DDAVP group is consistent with our
speculation. These findings support the implication
of porcine vWF for intravascular thrombosis and
systemic complement/coagulation abnormalities in
pulmonary xenotransplantation.
Porcine aGal epitope has the carbohydrate
structure similar to blood type B, and anti-B
antibodies in A and O individuals can recognize
both epitopes of aGal and blood type B [19].
Actually, the antibody to recognize both aGal and
blood type B comprises about 85% of natural anti-
B antibodies in A and O individuals. Because we
didn’t have any attempt to inhibit xenoreactive
antibodies and complement in this study, we were
afraid of possible massive hyperacute rejection
initiated by anti-B antibodies. Blood type AB
human blood would be the best to avoid any effect
of ABO mismatch but the low frequency of AB
type in our population forced us to recruit donors
with blood type B as a practical alternate. As for
donor animal, we should have used blood type O
swine, but in our situation, the pigs bred for
experimental purpose were not available and we
had to use farm pigs. In this process, the selection
of certain blood type of swine was impossible for
us. Accordingly, we cannot exclude the possibility
that anti-A antibodies along with anti-aGal
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antibodies in perfusion blood could have played a
role in injury of the lung in the case of blood type
A swine.
For comparisons between groups, we used
mixed model, a type of repeated measures
analysis. Its advantage is applicability to the
analysis of unbalanced data. The data of
repeated measurements from a subject have
autocorrelation. Analysis of longitudinal or
repeated measures data for balanced study design
can be done using repeated measures analysis of
variance. However, balanced data sets are rarely
obtained in studies and have caused serious
statistical analysis problem. The basic theory on
which mixed model are based holds with unbal-
anced data. In this study, we compared the trend
of the data according to the elapsing time, not
the data at a given time point. Accordingly, some
data set at a given time looked inconsistent with
the P-value which reflected significance of differ-
ence between groups for whole experimental
duration.
Pulmanary vascular resistance (PVR) is an
important variable of lung function but there was
no difference in the PVR between groups in this
study. This is not surprising given the fact that
there was no attempt to inhibit antibodies or
complement. However, in our perfusion setting,
the graft should be perfused gently by increasing
perfusion flow gradually at the beginning. As a
consequence, PVR and other hemodynamic
changes earlier than 5 to 10 min of perfusion were
not completely evaluated. Therefore, there might
be a more subtle effect on PVR early in the first
minutes of perfusion, which we might have missed.
Further improvement of ex-vivo perfusion setting
is necessary to evaluate earlier events of perfusion.
In this study, we clearly demonstrated the
beneficial effect of DDAVP pre-treatment in pul-
monary xenotransplantation using an ex-vivo per-
fusion model despite no additional strategies
against either xenoreactive antibodies or comple-
ment activation. Additionally, pre-treatment of
donor swine would not impose any harm on the
recipient. Although vWF depletion by DDAVP
would have a temporary and limited effect in
preventing pulmonary xenograft dysfunction, the-
oretically, the reduction of initial inflammation in
the graft would be desirable to minimize acute or
chronic rejection. So far, no single strategy has
been successful in prolonging the survival of
pulmonary xenotransplantation and multi-strate-
gic approaches are needed. Therefore, modulation
of vWF is expected to provide an additional benefit
to pulmonary xenotransplantation using geneti-
cally modified swine lacking aGal expression and/
or expressing human complement regulatory pro-
teins.
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